Analytical Data
-
Gene name
SLC17A5
- Application
-
Alternative Names
Sialin; H(+)/nitrate cotransporter; H(+)/sialic acid cotransporter; AST; Membrane glycoprotein HP59; Solute carrier family 17 member 5; Vesicular excitatory amino acid transporter; VEAT; SLC17A5; Homo sapiens; Human; AST
-
Species
Human
-
Source
HEK293
-
Tag
His;MBP;Flag
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NRA2-1
-
Expression Region
R2-H495
-
Protein Length
Partial
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC17A5, also known as the solute carrier family 17 member 5, encodes a protein primarily involved in the transport of neurotransmitters and other solutes across cellular membranes. This protein is notably linked to the functioning of lysosomal storage, particularly in the context of Salla disease, a genetic condition that arises from mutations in the SLC17A5 gene, leading to the accumulation of sialic acid in the body. Research on SLC17A5 recombinant proteins has gained attention due to their potential implications in understanding the pathophysiology of related disorders and developing therapeutic strategies. The availability of these proteins allows for detailed studies on their structure, function, and interaction with substrates, which is crucial for elucidating their role in cellular processes. Furthermore, SLC17A5's involvement in lysosomal function highlights its significance in the treatment of lysosomal storage diseases, making it a target for gene therapy and drug development. Overall, the study of SLC17A5 recombinant proteins is essential for advancing our knowledge of neurodegenerative conditions and related metabolic disorders, paving the way for innovative solutions to tackle these challenges.
